Clinical Efficacy of Drug Therapy in Gastrointestinal Cancers
A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Clinical Research of Cancer".
Deadline for manuscript submissions: 30 November 2025 | Viewed by 200
Special Issue Editors
2. Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy
Interests: surgical oncology; cancer surgery; laparoscopic surgery; colorectal surgery; gastrointestinal diseases
Interests: gastrointestinal cancers; tumor drug resistance; biomarkers; pharmacogenetics; pharmacogenomics; translational studies
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Among gastrointestinal cancers, colorectal cancer and gastric cancer are the most frequent and deadly tumors.
Recently, the use of adjuvant, neoadjuvant, and induction anticancer drug therapies, including not only classical chemotherapeutic agents but also innovative targeted therapeutics and various types of immunotherapy, has greatly improved the treatment strategies for these neoplasms in the locally advanced stages at risk of recurrence and also in the case of primary tumors with unresectable synchronous (liver or lung) metastases.
Clinical outcomes of up-to-date surgery and radiotherapy approaches have been complemented with anticancer drug therapy in a multidisciplinary contest.
By interfering with tumor signaling pathways, targeted therapies have the capability to suppress the growth and systemic spread of cancer cells.
Immunotherapies may also enhance immune surveillance by stimulating immune cells in the tumor microenvironment. Classical chemotherapeutic agents still represent the backbone of several drug combination therapies for all stages of these neoplasms.
Despite these advances, cancer drug resistance remains a major hurdle to a complete success, and a fair number of patients continue to experience disease recurrence and ultimately will die.
Thus, continuous efforts in the improvement of multidisciplinary treatments and in the discovery and development of innovative drugs based on high-quality clinical trials targeted to specific molecular determinants are still needed.
Prof. Dr. Francesco Tonelli
Prof. Dr. Enrico Mini
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- classical chemotherapy
- targeted therapeutics
- immunotherapy
- adjuvant therapy
- neoadjuvant therapy
- induction therapy
- multidisciplinary treatments
- gastric cancer
- colorectal cancer
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.
Further information on MDPI's Special Issue policies can be found here.
